Immunotech Laboratories BG announced the successful ITV-1 clinical trials Final Report completion

The conclusions about the results from ITV-1 clinical trials: 1. The application of the product ITV-1 shows good efficacy in patients with HIV-1 infection in its various stages – in 21 of them (68%) from the main group we note an increase in CD4 + T- lymphocytes; in 16 of…

Immunotech Laboratories BG announced successful completion of ITV-1 clinical trials on HIV/AIDS patients

Research Center: Department for treatment of acquired immune deficiency at the Specialized Hospital for Active Treatment of Infectious And Parasite Diseases – “Prof. Ivan Kirov”, Sofia, Bulgaria. Testing on human-volunteers, with HIV/AIDS, in whom ITV-1 has shown to be harmless, without any side effects, good tolerance, and a good treatment…

Immunotech Laboratories BG announced the successful approvement of ITV-1 clinical trials on HIV/AIDS patients in Bulgaria

Plan for the clinical trial The patients in the experimental group will conduct a total of 32 visits to the center for the clinical trial, and each therapeutic course will include 16 patient visits, with a break of 12 days between the two courses. The patients in the control group…

Synexa Life Sciences based in Cape Town, South Africa, has agreed to collaborate with Immunotech Laboratories

Synexa Life Sciences (Pty) Ltd. based in Cape Town, South Africa, has agreed to collaborate with ImmunoTech Laboratories Inc in their research activities to demonstrate the immunological activities of their propriety Irreversible Pepsin Fraction (IPF) which has shown to have potent adjuvant properties.         This new venture follows from a…

The Petition of Immunotech Laboratories, Inc. for Termination of Trading Suspension

The Issuer is a Nevada corporation with its principal business location in Monrovia, California. The Issuer’s common equity securities are traded on the OTC Link (“Pink Sheets”) under the ticker “IMMB”. The Issuer is not subject to reporting obligations found under Section 13 of the Exchange Act[3]. However, the Issuer…

The Securities and Exchange Commission suspended trade in four over-the-counter Ebola-related stocks

The Securities and Exchange Commission suspended trade in four over-the-counter Ebola-related stocks: Bravo Enterprises (OGNG), Immunotech Laboratories (IMMB), Myriad Interactive Media (MYRY) and Wholehealth Products (GWPC). The SEC cited a lack of publicly available information about the companies’ operations. The SEC can suspend trading in a stock for 10 days and generally…

Immunotech Laboratories, Inc. Enters into Agreement to Market Potential Ebola Virus Disease (“EVD”) Treatment and Implement Strategy for Company’s ITV-1 Infectious Diseases Treatment in Africa

Company Begins Research of Potential EVD Application of the Patented Proteins   Immunotech Laboratories, Inc. announced that they have successfully completed negotiations with Uldic Investment Pvt. Ltd. (Uldic), located in Zimbabwe, to pursue the development of market opportunities related to the deadly Ebola virus, and to conduct human clinical trials…

Immunotech Laboratories, Inc. announced that they have entered into negotiations with Uldic Investment Pvt. Ltd.

Immunotech Laboratories, Inc. (IMMB) announced that they have entered into negotiations with Uldic Investment Pvt. Ltd. , located in Zimbabwe, to pursue the development of market opportunities and Clinical Testing for the Company’s HIV/AIDS and Hepatitis C virus treatment (“ITV-1 Treatment”) in Africa, initially focusing on clinical testing for Hepatitis C…

Immunotech Laboratories BG have begun negotiations in Macedonia and Serbia for Phase III testing on human patients

Immunotech Laboratories, Inc. (IMMB) and Immunotech Laboratories BG recently announced the successful completion of Phase I and Phase II field trials in Bulgaria of the Company’s HIV/AIDS and Hepatitis C virus treatment (“ITV-1 Treatment”) and have begun negotiations for sites in Macedonia and Serbia for Phase III testing on human…

Immunotech Laboratories, Inc. announced successful completion of Phase I and Phase II Field Trials in Bulgaria of the Company’s Patented Treatment of the HIV/AIDS and Hepatitis C Viruses

Immunotech Laboratories, Inc. (IMMB) announced today that the Phase I and Phase II field trials in Bulgaria of the Company’s HIV/AIDS and Hepatitis C virus treatment (“ITV-1 Treatment”) have been successfully completed. The clinical test are being conducted through Immunotech Laboratories, BG (“IMMB-BG”) a 49% owned subsidiary of Immunotech Laboratories….